Concord Biotech Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Consistent revenue growth over the last four quarters, indicating strong demand for products.
Improved profit margins in the latest quarter, reflecting better cost management strategies.
Increased investment in R&D, signaling commitment to innovation and long-term growth.

NEGATIVES

Rising raw material costs have pressured margins, impacting profitability.
Quarterly sales growth slowed compared to previous quarters, raising concerns about future demand.
Higher debt levels noted in the latest quarter, potentially affecting financial stability.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue	194.83	262.35	240.80	318.97	215.80	310.18	244.22	203.99
Expenses	136.47	157.29	148.90	198.86	147.94	186.91	159.63	160.43
Operating Profit	58.36	105.05	91.90	120.11	67.86	123.27	84.59	43.56
Other Income	6.65	8.13	8.19	10.81	10.31	10.03	14.73	13.68
Interest	0.75	0.84	0.49	0.46	0.24	0.10	0.10	0.06
Depreciation	13.04	13.29	13.54	13.72	13.18	13.31	13.26	17.78
Profit Before Tax	71.04	109.70	103.10	128.72	79.52	130.33	101.15	58.73
Tax	16.54	28.69	25.53	33.70	19.93	34.59	25.23	14.67
Net Profit	54.49	81.02	77.57	95.02	59.59	95.74	75.92	44.06
Eps in Rs	5.21	7.74	7.41	9.08	5.70	9.15	7.26	4.21